Leptomeningeal carcinomatosis

Stuart A Grossman, Michael J. Krabak

Research output: Contribution to journalArticle

Abstract

Leptomeningeal carcinomatosis occurs in approximately 5% of patients with cancer. This disorder is being diagnosed with increasing frequency as patients live longer and as neuro-imaging studies improve. The most common cancers to involve the leptomeninges are breast cancer, lung cancer and melanomas. Tumour cells reach the leptominges by hematogenous spread or by direct extension from pre-existing lesions and are then disseminated throughout the neuroaxis by the flow of the cerebrospinal fluid. Patients present with signs and symptoms from injury to nerves that traverse the subarachnoid space, direct tumour invasion into the brain or spinal cord, alterations in blood supply to the nervous system, obstruction of normal cerebrospinal fluid (CSF) flow pathways, or general interference with brain function. The diagnosis is most commonly made by lumbar puncture although the CSF cytology is persistently negative in about 10% of patients with leptomeningeal carcinomatosis. Radiologic studies may reveal subarachnoid masses, diffuse contrast enhancement of the meninges, or hydrocephalus without a mass lesion. Without treatment, the median survival of patients with this disorder is 4-6 weeks and death occurs from progressive neurologic dysfunction. Early diagnosis and therapy is critical to preserving neurologic function. Radiation therapy to symptomatic sites and disease visible on neuroimaging studies and intrathecal chemotherapy increases the median survival to 3-6 months. The major favorable prognostic factors include excellent performance status, absence of serious fixed neurologic deficits, normal CSF flow scans, and absent or responsive systemic tumour. Aggressive therapy for this disorder is often accompanied by a necrotizing leukoencephalopathy which becomes symptomatic months after treatment with radiation and intrathecal methotrexate. As currently available therapies are toxic and provide limited benefits, novel approaches are being studied. Further information on the mechanisms of neurotoxicity from antineoplastic agents is critical to providing better outcomes for this increasing common complication of cancer.

Original languageEnglish (US)
Pages (from-to)103-119
Number of pages17
JournalCancer Treatment Reviews
Volume25
Issue number2
DOIs
StatePublished - Apr 1999

Fingerprint

Meningeal Carcinomatosis
Cerebrospinal Fluid
Neoplasms
Neurologic Manifestations
Nervous System
Lung Neoplasms
Leukoencephalopathies
Meninges
Subarachnoid Space
Spinal Puncture
Survival
Status Epilepticus
Poisons
Brain
Therapeutics
Hydrocephalus
Secondary Prevention
Neuroimaging
Methotrexate
Antineoplastic Agents

Keywords

  • Breast cancer
  • Cerebrospinal fluid
  • CNS cancer
  • Cytarabine
  • Intrathecal chemotherapy
  • Leptomeningeal carcinomatosis
  • Lung cancer
  • Melanoma
  • Meningeal carcinomatosis
  • Methotrexate
  • Neoplastic meningitis
  • Radiation therapy
  • Thiotepa

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Leptomeningeal carcinomatosis. / Grossman, Stuart A; Krabak, Michael J.

In: Cancer Treatment Reviews, Vol. 25, No. 2, 04.1999, p. 103-119.

Research output: Contribution to journalArticle

Grossman, Stuart A ; Krabak, Michael J. / Leptomeningeal carcinomatosis. In: Cancer Treatment Reviews. 1999 ; Vol. 25, No. 2. pp. 103-119.
@article{df77d9882bc042c18f3f9ed6ca36ff51,
title = "Leptomeningeal carcinomatosis",
abstract = "Leptomeningeal carcinomatosis occurs in approximately 5{\%} of patients with cancer. This disorder is being diagnosed with increasing frequency as patients live longer and as neuro-imaging studies improve. The most common cancers to involve the leptomeninges are breast cancer, lung cancer and melanomas. Tumour cells reach the leptominges by hematogenous spread or by direct extension from pre-existing lesions and are then disseminated throughout the neuroaxis by the flow of the cerebrospinal fluid. Patients present with signs and symptoms from injury to nerves that traverse the subarachnoid space, direct tumour invasion into the brain or spinal cord, alterations in blood supply to the nervous system, obstruction of normal cerebrospinal fluid (CSF) flow pathways, or general interference with brain function. The diagnosis is most commonly made by lumbar puncture although the CSF cytology is persistently negative in about 10{\%} of patients with leptomeningeal carcinomatosis. Radiologic studies may reveal subarachnoid masses, diffuse contrast enhancement of the meninges, or hydrocephalus without a mass lesion. Without treatment, the median survival of patients with this disorder is 4-6 weeks and death occurs from progressive neurologic dysfunction. Early diagnosis and therapy is critical to preserving neurologic function. Radiation therapy to symptomatic sites and disease visible on neuroimaging studies and intrathecal chemotherapy increases the median survival to 3-6 months. The major favorable prognostic factors include excellent performance status, absence of serious fixed neurologic deficits, normal CSF flow scans, and absent or responsive systemic tumour. Aggressive therapy for this disorder is often accompanied by a necrotizing leukoencephalopathy which becomes symptomatic months after treatment with radiation and intrathecal methotrexate. As currently available therapies are toxic and provide limited benefits, novel approaches are being studied. Further information on the mechanisms of neurotoxicity from antineoplastic agents is critical to providing better outcomes for this increasing common complication of cancer.",
keywords = "Breast cancer, Cerebrospinal fluid, CNS cancer, Cytarabine, Intrathecal chemotherapy, Leptomeningeal carcinomatosis, Lung cancer, Melanoma, Meningeal carcinomatosis, Methotrexate, Neoplastic meningitis, Radiation therapy, Thiotepa",
author = "Grossman, {Stuart A} and Krabak, {Michael J.}",
year = "1999",
month = "4",
doi = "10.1053/ctrv.1999.0119",
language = "English (US)",
volume = "25",
pages = "103--119",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Leptomeningeal carcinomatosis

AU - Grossman, Stuart A

AU - Krabak, Michael J.

PY - 1999/4

Y1 - 1999/4

N2 - Leptomeningeal carcinomatosis occurs in approximately 5% of patients with cancer. This disorder is being diagnosed with increasing frequency as patients live longer and as neuro-imaging studies improve. The most common cancers to involve the leptomeninges are breast cancer, lung cancer and melanomas. Tumour cells reach the leptominges by hematogenous spread or by direct extension from pre-existing lesions and are then disseminated throughout the neuroaxis by the flow of the cerebrospinal fluid. Patients present with signs and symptoms from injury to nerves that traverse the subarachnoid space, direct tumour invasion into the brain or spinal cord, alterations in blood supply to the nervous system, obstruction of normal cerebrospinal fluid (CSF) flow pathways, or general interference with brain function. The diagnosis is most commonly made by lumbar puncture although the CSF cytology is persistently negative in about 10% of patients with leptomeningeal carcinomatosis. Radiologic studies may reveal subarachnoid masses, diffuse contrast enhancement of the meninges, or hydrocephalus without a mass lesion. Without treatment, the median survival of patients with this disorder is 4-6 weeks and death occurs from progressive neurologic dysfunction. Early diagnosis and therapy is critical to preserving neurologic function. Radiation therapy to symptomatic sites and disease visible on neuroimaging studies and intrathecal chemotherapy increases the median survival to 3-6 months. The major favorable prognostic factors include excellent performance status, absence of serious fixed neurologic deficits, normal CSF flow scans, and absent or responsive systemic tumour. Aggressive therapy for this disorder is often accompanied by a necrotizing leukoencephalopathy which becomes symptomatic months after treatment with radiation and intrathecal methotrexate. As currently available therapies are toxic and provide limited benefits, novel approaches are being studied. Further information on the mechanisms of neurotoxicity from antineoplastic agents is critical to providing better outcomes for this increasing common complication of cancer.

AB - Leptomeningeal carcinomatosis occurs in approximately 5% of patients with cancer. This disorder is being diagnosed with increasing frequency as patients live longer and as neuro-imaging studies improve. The most common cancers to involve the leptomeninges are breast cancer, lung cancer and melanomas. Tumour cells reach the leptominges by hematogenous spread or by direct extension from pre-existing lesions and are then disseminated throughout the neuroaxis by the flow of the cerebrospinal fluid. Patients present with signs and symptoms from injury to nerves that traverse the subarachnoid space, direct tumour invasion into the brain or spinal cord, alterations in blood supply to the nervous system, obstruction of normal cerebrospinal fluid (CSF) flow pathways, or general interference with brain function. The diagnosis is most commonly made by lumbar puncture although the CSF cytology is persistently negative in about 10% of patients with leptomeningeal carcinomatosis. Radiologic studies may reveal subarachnoid masses, diffuse contrast enhancement of the meninges, or hydrocephalus without a mass lesion. Without treatment, the median survival of patients with this disorder is 4-6 weeks and death occurs from progressive neurologic dysfunction. Early diagnosis and therapy is critical to preserving neurologic function. Radiation therapy to symptomatic sites and disease visible on neuroimaging studies and intrathecal chemotherapy increases the median survival to 3-6 months. The major favorable prognostic factors include excellent performance status, absence of serious fixed neurologic deficits, normal CSF flow scans, and absent or responsive systemic tumour. Aggressive therapy for this disorder is often accompanied by a necrotizing leukoencephalopathy which becomes symptomatic months after treatment with radiation and intrathecal methotrexate. As currently available therapies are toxic and provide limited benefits, novel approaches are being studied. Further information on the mechanisms of neurotoxicity from antineoplastic agents is critical to providing better outcomes for this increasing common complication of cancer.

KW - Breast cancer

KW - Cerebrospinal fluid

KW - CNS cancer

KW - Cytarabine

KW - Intrathecal chemotherapy

KW - Leptomeningeal carcinomatosis

KW - Lung cancer

KW - Melanoma

KW - Meningeal carcinomatosis

KW - Methotrexate

KW - Neoplastic meningitis

KW - Radiation therapy

KW - Thiotepa

UR - http://www.scopus.com/inward/record.url?scp=0033117810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033117810&partnerID=8YFLogxK

U2 - 10.1053/ctrv.1999.0119

DO - 10.1053/ctrv.1999.0119

M3 - Article

C2 - 10395835

AN - SCOPUS:0033117810

VL - 25

SP - 103

EP - 119

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 2

ER -